Clinical trial
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
NCT00137839 · Pasi A. Janne, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00137839 |
|---|---|
| Title | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung |
| Official title | A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung |
| Lead sponsor | Pasi A. Janne, MD, PhD, Other |
| Collaborators | Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital Beth Israel Deaconess Medical Center Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 84 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Jul 1, 2019 |
| First posted | Aug 30, 2005 |
| Last update posted | Dec 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: